A novel immuno-PET/CT imaging technique has identified and validated a potent biomarker for nasopharyngeal cancer (NPC). The biomarker, CD70, is highly and constantly expressed in NPCs, and CD70-targeted immuno-PET/CT have proven effective in accurately detecting primary and metastatic NPC lesions. This research, published in the June issue of The Journal of Nuclear Medicine, has the potential to enhance diagnosis and guide personalized therapies for NPC patients.

In a bold step to transform cancer care, Mayo Clinic is bringing new hope for patients diagnosed with the most aggressive and treatment-resistant cancers. Mayo Clinic opened the new 228,000-square-foot Duan Family Building at its Jacksonville, Florida location. The building will house the first carbon ion therapy program in the Western Hemisphere, and advanced technology that can seamlessly deliver both carbon ions and protons to treat the same tumor. 

Human papillomavirus (HPV) can drive tumor development in some rare sinonasal squamous cell carcinomas (SNSCCs), according to a new comprehensive study of these tumors from investigators at the Johns Hopkins University School of Medicine and the Johns Hopkins Kimmel Cancer Center. The researchers also identified common mutations among these cancers and a potential combination treatment during the study, which was partially supported by the National Institutes of Health.

The diagnosis of hepatic precancerous lesions (HPC) and early hepatocellular carcinoma (HCC) has significant public health implications and holds the potential to reduce the global burden of HCC. This study aimed to identify molecular features and biomarkers associated with HPC progression and early HCC development.

BUFFALO, NY – June 11, 2025 – A new research paper was published in Volume 16 of Oncotarget on May 29, 2025, titled “Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib.”

Fat mass and obesity-associated protein (FTO) has been linked to various cancers, though its role in hepatocellular carcinoma (HCC) remains unclear. This study aimed to investigate FTO expression, its clinical relevance, functional role in HCC progression, and the underlying molecular mechanisms.